Effective pressure and treatment duration of high hydrostatic pressure to prepare melanoma vaccines

Liu,Kai; Yan,Shuai; Ma,Zhanchuan; Liu,Bin

doi:10.3892/ol.2020.11657

Effective pressure and treatment duration of high hydrostatic pressure to prepare melanoma vaccines

Authors:
- Kai Liu
- Shuai Yan
- Zhanchuan Ma
- Bin Liu
View Affiliations

Affiliations: Department of Hand and Foot Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Operating Room, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Institute of Immunology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: May 21, 2020 https://doi.org/10.3892/ol.2020.11657
Pages: 1135-1142
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Current therapeutic methods for melanoma have numerous limitations, and thus the improvement of such treatment methods are essential. One possible option is the vaccination of autologous inactivated tumor cells. The primary indispensable principles of a cell‑based melanoma vaccine include: i) Entire inactivation of melanoma cells; ii) retaining the immunogenicity of melanoma cells; and iii) adherence to laws and ethical guidelines. However, traditional methods for the production of the vaccine, such as ultrasonic, chemotherapeutics and freeze‑thawing, have some juridical or therapeutic constraints. Therefore, the present study used high hydrostatic pressure (HHP) to inactivate malignant cells, and treated B16‑F10 tumor cells with different pressures (≥50 MPa) and different durations (≥1 min). It was identified that tumor cells in vitro lost their proliferative ability, but retained their immunogenicity following treatment. Furthermore, the vaccination of the melanoma cells significantly suppressed their oncogenesis. Collectively, the present results suggest that HHP treatment may be an economically viable and effective measure to develop a melanoma vaccine, when pressure was ≥200 MPa and the treatment duration was ≥30 min.

View Figures

View References

1	Jaklitsch MT, Grondin SC and Sugarbaker DJ: Treatment of malignant mesothelioma. World J Surg. 25:210–217. 2001. View Article : Google Scholar : PubMed/NCBI
2	Spagnolo F, Boutros A, Tanda E and Queirolo P: The adjuvant treatment revolution for high-risk melanoma patients. Semin Cancer Biol. 59:283–289. 2019. View Article : Google Scholar : PubMed/NCBI
3	Lacy A and O'Kennedy R: Studies on coumarins and coumarin- related compounds to determine their therapeutic role in the treatment of cancer. Curr Pharm Des. 10:3797–3811. 2004. View Article : Google Scholar : PubMed/NCBI
4	Spiegel D and Classen C: Group therapy for cancer patients: A research-based handbook of psychosocial care. 1st edition Basic Books; New York, NY: 2000
5	Hutchison S, Sahay B, de Mello SC, Sayour EJ, Lejeune A, Szivek A, Livaccari AM, Fox-Alvarez S, Salute M, Powers L and Milner RJ: Characterization of myeloid-derived suppressor cells and cytokines GM-CSF, IL-10 and MCP-1 in dogs with malignant melanoma receiving a GD3-based immunotherapy. Vet Immunol Immunopathol. 216:1099122019. View Article : Google Scholar : PubMed/NCBI
6	Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F and Del Vecchio M: Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma. Tumori. 105:465–473. 2019. View Article : Google Scholar : PubMed/NCBI
7	Dolan DE and Gupta S: PD-1 pathway inhibitors: Changing the landscape of cancer immunotherapy. Cancer Control. 21:231–237. 2014. View Article : Google Scholar : PubMed/NCBI
8	Khalil DN, Smith EL, Brentjens RJ and Wolchok JD: The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 13:273–290. 2016. View Article : Google Scholar : PubMed/NCBI
9	Li SY, Liu Y, Xu CF, Shen S, Sun R, Du XJ, Xia JX, Zhu YH and Wang J: Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation. J Control Release. 231:17–28. 2016. View Article : Google Scholar : PubMed/NCBI
10	Montagne K, Onuma Y, Ito Y, Aiki Y, Furukawa KS and Ushida T: High hydrostatic pressure induces pro-osteoarthritic changes in cartilage precursor cells: A transcriptome analysis. PLoS One. 12:e01832262017. View Article : Google Scholar : PubMed/NCBI
11	Bol KF, Aarntzen EH, Pots JM, Olde Nordkamp MA, van de Rakt MW, Scharenborg NM, de Boer AJ, van Oorschot TG, Croockewit SA, Blokx WA, et al: Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. Cancer Immunol Immunother. 65:327–339. 2016. View Article : Google Scholar : PubMed/NCBI
12	Klippstein R and Pozo D: Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine. 6:523–529. 2010. View Article : Google Scholar : PubMed/NCBI
13	Schummer V, Flindt S and Hinz T: Tumor vaccines and peptide-loaded dendritic cells (DCs). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 58:1254–1258. 2015.(In German). View Article : Google Scholar : PubMed/NCBI
14	Gross S, Erdmann M, Haendle I, Voland S, Berger T, Schultz E, Strasser E, Dankerl P, Janka R, Schliep S, et al: Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. JCI Insight. 2:914382017. View Article : Google Scholar : PubMed/NCBI
15	Hu Z, Ma Y, Shang Z, Hu S, Liang K, Liang W, Xing X, Wang Y and Du X: Improving immunotherapy for colorectal cancer using dendritic cells combined with anti-programmed death-ligand in vitro. Oncol Lett. 15:5345–5351. 2018.PubMed/NCBI
16	Rosenblatt J and Avigan D: Cellular immunotherapy for multiple myeloma. Best Pract Res Clin Haematol. 21:559–577. 2008. View Article : Google Scholar : PubMed/NCBI
17	Copier J, Ward S and Dalgleish A: Cell based cancer vaccines: Regulatory and commercial development. Vaccine. 25 (Suppl 2):B35S–B46S. 2007. View Article : Google Scholar
18	Bliznyuk A, Grossman Y and Moskovitz Y: The effect of high pressure on the NMDA receptor: Molecular dynamics simulations. Sci Rep. 9:108142019. View Article : Google Scholar : PubMed/NCBI
19	Weiss EM, Meister S, Janko C, Ebel N, Schlücker E, Meyer-Pittroff R, Fietkau R, Herrmann M, Gaipl U and Frey B: High hydrostatic pressure treatment generates inactivated mammalian tumor cells with immunogeneic features. J Immunotoxicol. 7:194–204. 2010. View Article : Google Scholar : PubMed/NCBI
20	Franco I, Castillo E, Perez MD, Calvo M and Sanchez L: Effects of hydrostatic high pressure on the structure and antibacterial activity of recombinant human lactoferrin from transgenic rice. Biosci Biotechnol Biochem. 76:53–59. 2012. View Article : Google Scholar : PubMed/NCBI
21	Zhang Y, Dai B, Deng Y and Zhao Y: In vitro anti-inflammatory and antioxidant activities and protein quality of high hydrostatic pressure treated squids (Todarodes pacificus). Food Chem. 203:258–266. 2016. View Article : Google Scholar : PubMed/NCBI
22	Chen H, Xiao G, Xu Y, Yu Y, Wu J and Zou B: High hydrostatic pressure and Co-fermentation by lactobacillus rhamnosus and gluconacetobacter xylinus improve flavor of yacon-litchi-longan juice. Foods. 8:E3082019. View Article : Google Scholar : PubMed/NCBI
23	Woo HJ, Park JB, Kang JH, Chun HH and Song KB: Combined treatment of high hydrostatic pressure and cationic surfactant washing to inactivate listeria monocytogenes on fresh-cut broccoli. J Microbiol Biotechnol. 29:1240–1247. 2019. View Article : Google Scholar : PubMed/NCBI
24	Yamamoto K: Food processing by high hydrostatic pressure. Biosci Biotechnol Biochem. 81:672–679. 2017. View Article : Google Scholar : PubMed/NCBI
25	Huang R, Ye M, Li X, Ji L, Karwe M and Chen H: Evaluation of high hydrostatic pressure inactivation of human norovirus on strawberries, blueberries, raspberries and in their purees. Int J Food Microbiol. 223:17–24. 2016. View Article : Google Scholar : PubMed/NCBI
26	Diehl P, Schauwecker J, Mittelmeier W and Schmitt M: High hydrostatic pressure, a novel approach in orthopedic surgical oncology to disinfect bone, tendons and cartilage. Anticancer Res. 28:3877–3883. 2008.PubMed/NCBI
27	Barnes CA, Robertson AJ, Louis JM, Anfinrud P and Bax A: Observation of β-amyloid peptide oligomerization by pressure-jump NMR spectroscopy. J Am Chem Soc. 141:13762–13766. 2019. View Article : Google Scholar : PubMed/NCBI
28	Shearer AE and Kniel KE: High hydrostatic pressure for development of vaccines. J Food Prot. 72:1500–1508. 2009. View Article : Google Scholar : PubMed/NCBI
29	Golub M, Lehofer B, Martinez N, Ollivier J, Kohlbrecher J, Prassl R and Peters J: High hydrostatic pressure specifically affects molecular dynamics and shape of low-density lipoprotein particles. Sci Rep. 7:460342017. View Article : Google Scholar : PubMed/NCBI
30	Winter R and Dzwolak W: Temperature-pressure configurational landscape of lipid bilayers and proteins. Cell Mol Biol (Noisy-le-grand). 50:397–417. 2004.PubMed/NCBI
31	Winter R: Synchrotron X-ray and neutron small-angle scattering of lyotropic lipid mesophases, model biomembranes and proteins in solution at high pressure. Biochim Biophys Acta. 1595:160–184. 2002. View Article : Google Scholar : PubMed/NCBI
32	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals: Guide for the Care and Use of Laboratory Animals. National Academies Press (US); Washington, DC: 2011
33	Varela A, Salagianni M, Galani I, Andreakos E and Davos CH: The role of TLR7 receptors on cardiac and vascular function of ApoE-/-mice. Eur J Echocardiography. 12 (Suppl 2):P7572011.
34	Leary SL, Underwood W, Anthony R, Cartner S, Corey D, Grandin T, Greenacre C, Gwaltney-Bran S, McCrackin M and Meyer R: AVMA guidelines for the euthanasia of animals: 2013 edition. American Veterinary Medical Association Schaumburg; IL: 2013
35	Zhuang X, Wu T, Zhao Y, Hu X, Bao Y, Guo Y, Song Q, Li G, Tan S and Zhang Z: Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K b and H-2D b-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma. J Control Release. 228:26–37. 2016. View Article : Google Scholar : PubMed/NCBI
36	De Gruijl TD, van den Eertwegh AJ, Pinedo HM and Scheper RJ: Whole-cell cancer vaccination: From autologous to allogeneic tumor-and dendritic cell-based vaccines. Cancer Immunol Immunother. 57:1569–1577. 2008. View Article : Google Scholar : PubMed/NCBI
37	Frey B, Schildkopf P, Rödel F, Weiss EM, Munoz LE, Herrmann M, Fietkau R and Gaipl US: AnnexinA5 renders dead tumor cells immunogenic-implications for multimodal cancer therapies. J Immunotoxicol. 6:209–216. 2009. View Article : Google Scholar : PubMed/NCBI
38	Estrela-Llopis VR, Chevichalova AV, Tregubova NA, Shishko ED and Litvin PM: Platinum nanoparticles with adsorptive layer of Chlorella vulgaris polysaccharides inactivate tumor cells of ascitic ehrlich carcinoma, ovarian cancer and leukemia. Nanocomposites, nanophotonics, nanobiotechnology, and applications. Fesenko O and Yatsenko L: 156. Springer Proceedings in Physics; Springer, Cham: 2015
39	Hollingsworth RE and Jansen K: Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 4:72019. View Article : Google Scholar : PubMed/NCBI
40	Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L and Kroemer G: Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis. 14:364–375. 2009. View Article : Google Scholar : PubMed/NCBI
41	Melief CJM, van Hall T, Arens R, Ossendorp F and van der Burg SH: Therapeutic cancer vaccines. J Clin Invest. 125:3401–3412. 2015. View Article : Google Scholar : PubMed/NCBI
42	Gross M and Jaenicke R: Proteins under pressure: The influence of high hydrostatic pressure on structure, function and assembly of proteins and protein complexes. Eur J Biochem. 221:617–630. 1994. View Article : Google Scholar : PubMed/NCBI
43	Urbanova L, Hradilova N, Moserova I, Vosahlikova S, Sadilkova L, Hensler M, Spisek R and Adkins I: High hydrostatic pressure affects antigenic pool in tumor cells: Implication for dendritic cell-based cancer immunotherapy. Immunol Lett. 187:27–34. 2017. View Article : Google Scholar : PubMed/NCBI
44	Fucikova J, Moserova I, Truxova I, Hermanova I, Vancurova I, Partlova S, Fialova A, Sojka L, Cartron PF, Houska M, et al: High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer. 135:1165–1177. 2014. View Article : Google Scholar : PubMed/NCBI
45	Weiss EM, Wunderlich R, Ebel N, Rubner Y, Schlücker E, Meyer-Pittroff R, Ott OJ, Fietkau R, Gaipl US and Frey B: Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Front Oncol. 2:1322012. View Article : Google Scholar : PubMed/NCBI
46	Gaipl US, Munoz LE, Rödel F, Pausch F, Frey B, Brachvogel B, von der Mark K and Pöschl E: Modulation of the immune system by dying cells and the phosphatidylserine-ligand annexin A5. Autoimmunity. 40:254–259. 2007. View Article : Google Scholar : PubMed/NCBI
47	Boonyaratanakornkit BB, Park CB and Clark DS: Pressure effects on intra-and intermolecular interactions within proteins. Biochim Biophys Acta. 1595:235–249. 2002. View Article : Google Scholar : PubMed/NCBI
48	Korn A, Frey B, Sheriff A, Gaipl U, Franz S, Meyer-Pittroff R, Bluemelhuber G and Herrmann M: High hydrostatic pressure inactivated human tumour cells preserve their immunogenicity. Cell Mol Biol (Noisy-le-grand). 50:469–477. 2004.PubMed/NCBI
49	Frey B, Franz S, Sheriff A, Korn A, Bluemelhuber G, Gaipl U, Voll R, Meyer-Pittroff R and Herrmann M: Hydrostatic pressure induced death of mammalian cells engages pathways related to apoptosis or necrosis. Cell Mol Biol (Noisy-le-grand). 50:459–467. 2004.PubMed/NCBI
50	Patterson MF: Microbiology of pressure-treated foods. J Appl Microbiol. 98:1400–1409. 2005. View Article : Google Scholar : PubMed/NCBI
51	Seitz C, Rückert M, Deloch L, Weiss EM, Utz S, Izydor M, Ebel N, Schlücker E, Fietkau R, Gaipl US and Frey B: Tumor cell-based vaccine generated with high hydrostatic pressure synergizes with radiotherapy by generating a favorable anti-tumor immune microenvironment. Front Oncol. 9:8052019. View Article : Google Scholar : PubMed/NCBI
52	Rao J, Dragulescu-Andrasi A and Yao H: Fluorescence imaging in vivo: Recent advances. Curr Opin Biotechnol. 18:17–25. 2007. View Article : Google Scholar : PubMed/NCBI
53	Chang EY, Chen CH, Ji H, Wang TL, Hung K, Lee BP, Huang AY, Kurman RJ, Pardoll DM and Wu T: Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer. 86:725–730. 2000. View Article : Google Scholar : PubMed/NCBI